Immunotherapy Prevents Colon Cancer Recurrence for Five Years in Landmark Study

Long-term results from the NICHE-2 study, published in The Lancet, show that a brief course of immunotherapy given before surgery prevented disease recurrence for five years in all patients with non-metastatic mismatch repair-deficient (dMMR) colon cancer. All 111 patients in the primary efficacy group remained alive and recurrence-free at their most recent follow-up. This landmark finding highlights the potential to significantly reshape treatment for this specific colon cancer patient population.